Congress Materials – American Society of Hematology (ASH 2024)
2024 American Society of Hematology | Dec 7-10 | San Diego, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 MajesTEC-1 Study
Niels W.C.J. van de Donk, Ajai Chari, Lionel Karlin, Amrita Y. Krishnan, Katarina Uttervall, Thomas Chalopin, Laura Rosiñol, Albert Oriol, Jeffrey V. Matous, Manisha Bhutani, Cesar Rodriguez, Natalia A. Quijano Cardé, Yue Guo, Caroline Hodin, Clarissa Uhlar, Tara Stephenson, Athena Zuppa, Margaret Doyle, Katherine Chastain, Alfred L. Garfall
Association Between Dose Reduction and Duration of Therapy in Patients Receiving Ibrutinib or Acalabrutinib for Chronic Lymphocytic Leukemia: A Medical Chart Review Study
Mazyar Shadman, Lindsey Roeker, Javier Pinilla-Ibarz, Bhavini Srivastava, Sudeep Karve, Gabriel S. Krigsfeld, Erin Franceschini, Chadi Saifan, Siddharth Karanth, Ravi K. Goyal, Julien Rombi, Deborah M. Stephens
Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
Emma Searle, Christian Recher, Maher Abdul-Hay, Sameem Abedin, Ibrahim Aldoss, Ana Alfonso Piérola, Juan M. Alonso-Domínguez, Patrice Chevallier, Carrye Cost, Nikki Daskalakis, Richard Dillon, Neil Dunavin, Jordi Esteve, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Hagop M. Kantarjian, Min Chul Kwon, Anita J. Kumar, Teng Fong Ng, Kathryn Packman, Ulrike Philippar, Arnaud Pigneux, Olga Salamero, Madhu Sanga, Prathap Nagaraja Shastri, Richard M. Stone, Peter T. Tan, Trevor Tucker, Paresh Vyas, Sylvain Garciaz
Characteristics, Treatment Patterns, and Outcomes of Patients With Multiple Myeloma Retreated With Daratumumab in Real-World Clinical Practice in the USA
Sikander Ailawadhi, Sarah M. Larson, Shannon Ferrante, Nicole Rafalko, Niodita Gupta-Werner, Jennifer S. Harper, Rohan Medhekar, Marjohn Armoon, Annelore Cortoos, Shuchita Kaila, Shebli Atrash
Ciltacabtagene Autoleucel (Cilta-cel) vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) After 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 CARTITUDE-4 Trial
Rakesh Popat, Albert Oriol, Michele Cavo, Lionel Karlin, Irit Avivi Mazza, Wilfried Roeloffzen, Seok Jin Kim, Brea Lipe, Noffar Bar, Noemi Horvath, Andrew Spencer, Chang-Ki Min, Diana Chen, Quanlin Li, Katherine Li, Ana Slaughter, Carolina Lonardi, Nina Benachour, Arnab Ghosh, Martin Vogel, Nikoletta Lendvai, Tamar Lengil, Nitin Patel, Octavio Costa Filho, Erika Florendo, Yi Lin
Circulating Tumor Cells as a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated With Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the PERSEUS Study
Luca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, Mark van Duin, Niels W.C.J. Van De Donk, Mattia D’Agostino, Evangelos Terpos, Diego Vieyra, Ricardo M. Attar, Anna Sitthi-Amorn, Robin Carson, Michel Delforge, Christoph Driessen, Roman Hajek, Mario Boccadoro, Hermann Einsele, Annette Vangsted, Vincent H.J. Van Der Velden, Fredrik Schjesvold, Artur Jurczyszyn, Meral Beksac, Andrew Spencer, Annemiek Broijl, Tom Cupedo, Philippe Moreau, Pieter Sonneveld
Clinical Outcomes in Black Patients With Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses From the Phase 1/2 MonumenTAL-1 Study
Carolina Schinke, Gareth Morgan, Luciano J. Costa, Natalie Callander, Don A. Stevens, Jesus G. Berdeja, Brea Lipe, Sagar Lonial, Marie-Christiane Vekemans, Ravi Vij, Philippe Moreau, Paula Rodríguez-Otero, Anna Sureda Balari, Thomas Renaud, Jaszianne Tolbert, Bonnie W. Lau, Brandi W. Hilder, Tara J. Masterson, Michela Campagna, Veronique Vreys, Christoph Heuck, Colleen Kane, Kathleen S. Gray, Deeksha Vishwamitra, Indrajeet Singh, Joy Gong, Xiang Qin, Larysa Sanchez
Consistently High 5.5-Year Progression-Free Survival Rates in Patients With and Without Bulky Baseline Lymphadenopathy ≥5 cm Are Associated With High Undetectable Minimal Residual Disease Rates After First-Line Treatment With Fixed- Duration Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Phase 2 CAPTIVATE Study
William G. Wierda, Ryan Jacobs, Paul M. Barr, John N. Allan, Tanya Siddiqi, Alessandra Tedeschi, Thomas J. Kipps, Susan M. O'Brien, Xavier C. Badoux, Andrea Visentin, Masa Lasica, Dennis A. Carney, Anna Elinder Camburn, Javier De la Serna, Edith Szafer Glusman, Cathy Zhou, Jutta K. Neuenburg, Lynne Neumayr, Anita Szoke, James P. Dean, Paolo Ghia, Constantine S. Tam
CRISPR/Cas9 Library Screens Identified Atp2a2 as an In Vivo Specific Tumor Suppressor in Myeloid Neoplasms
Ruka Shimura, Moe Tamura, Keita Yamamoto, Kohei Iida, Shuhei Asada, Emi Sugimoto, E. Christine Pietsch, Barbara A. Weir, Ramona Crescenzo, Glenn S. Cowley, Ricardo M. Attar, Ulrike Philippar, Satoshi Yamasaki, Taisei Hirouchi, Kaoru Uchimaru, Toshio Kitamura, Susumu Goyama
Daratumumab + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus VRd Alone in Patients With Newly Diagnosed Multiple Myeloma Ineligible for SCT or for Whom SCT is Not Planned as Initial Therapy: Analysis of Minimal Residual Disease in the Phase 3 CEPHEUS Trial
Sonja Zweegman, Thierry Facon, Vania Hungria, Nizar J. Bahlis, Christopher P. Venner, Marc Braunstein, Ludek Pour, Josep Marti Tutusaus, Supratik Basu, Yael C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Maciej Legiec, Meral Beksac, Angelo Maiolino, Hiroyuki Takamatsu, Aurore Perrot, Mehmet Turgut, Weiping Liu, Jianping Wang, Katherine Chastain, Jessica Vermeulen, Maria Krevvata, Lorena Lopez-Masi, Jodi Carey, Melissa Rowe, Robin Carson, Saad Z. Usmani
Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) After Transplant: Analysis of the Phase 3 AURIGA Study Among Clinically Relevant Subgroups
Laahn Foster, Larry D. Anderson, Jr., Alfred Chung, Chakra Chaulagain, Erin Pettijohn, Andrew J. Cowan, Caitlin Costello, Sarah M. Larson, Douglas W. Sborov, Kenneth H. Shain, Rebecca Silbermann, Peter M. Voorhees, Maria Krevvata, Huiling Pei, Sharmila Patel, Vipin Khare, Annelore Cortoos, Robin Carson, Thomas S. Lin, Ashraf Z. Badros
Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma
Jocelyn R. Wang, Jennifer Hayden, Yiyang Yue, Craig S. Meyer, Ryan W. Gan, Youyi Zhang, Benjamin Ackerman, Pranay Mohanty, James Roose, Jennifer L. Lund, Sebastian Schneeweiss, Janick Weberpals, Omar Nadeem, Sikander Ailawadhi, Noopur Raje, Smith Giri, Juned Siddique, Laura Hester, Kelly Reid, Robin Carson, Khaled Sarsour, Ashita Batavia
Discovery of JNJ-89853413, a First-in-Class CD33xVδ2 T-Cell Engager for the Treatment of Acute Myeloid Leukemia
Sara El Ashkar, Lorena Kallal, Kavita Raman, Ranjeet Prasad Dash, Nirav Shah, Lore Delbroek, Lénárd Kertész, Heleen Van Aacker, Steffie Junius, Ivo Cornelissen, Surendar Arumugam, Lauren Gerloff, Kathryn Bradford, E. Christine Pietsch, Leopoldo Luistro, Bethany Mattson, Christina Guttke, Karim Safer, Janine Arts, Sonal Patel, Ulrike Philippar
Dosing Patterns and Early Safety and Effectiveness Outcomes in Patients with Multiple Myeloma Treated with Teclistamab in the Community Setting
Timothy C. Beer, Gloria H.J. Graf, Dee Lin, Mariana Fernandez, Margaret Doyle, Laura L. Hester, Bingcao Wu, Stephen Huo
Duration of Therapy in Patients With Waldenström Macroglobulinemia Undergoing Dose Reductions of First-Line Ibrutinib: A Real-World Analysis
Shayna Sarosiek, Monika Salkar, Barnabie Agatep, Barton Jones, Michelle Pacia, Chadi Saifan, Shaffee Bacchus, Sudeep Karve, Jonas Paludo
Efficacy of CARVYKTI in CARTITUDE-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting
Rafael Fonseca, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Seina Lee, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Winfried Alsdorf, Margherita Ursi
Evolution of Treatment Patterns and Survival Outcomes in European Patients With Multiple Myeloma from 2012–2023 through the HONEUR Federated Data Network
Markus Rückert, Guillaume Azarias, Mamta Garg, Ceri Bygrave, Hannah Belcher, Clare Hague, Kristina Bardenheuer, Wout Vekemans, Morten Salomo, Blanca Gros Otero, Nolen Perualila, Michel Van Speybroeck, Joris Diels, Vladimir Maisnar, Ivan Špička, Roman Hájek
First-Line Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients With Chronic Lymphocytic Leukemia: GLOW Study 67-Month Follow-up and Adverse Event-Free Progression-Free Survival Analysis
Carsten U. Niemann, Talha Munir, Carolyn Owen, George Follows, José-Ángel Hernández-Rivas, Ohad Benjamini, Ann Janssens, Mark-David Levin, Tadeusz Robak, Martin Simkovic, Sergey Voloshin, Vladimir I. Vorobyev, Loic Ysebaert, Natasha Schuier, Kurt Baeten, Ping Xu, Nguyet Tran, Bennett Levitan, Claire Kavanagh, Arnon P. Kater
Frontline Treatment Patterns in Patients With Newly Diagnosed Multiple Myeloma - Real-World Evidence From a Large Community-Based Oncology Practice Network in the US
Lucio Gordan, Amanda Warner, Hannah Granger, Amy Ming, Cindy Chen, Nicole Rafalko, Jennifer S. Harper, Niodita Gupta-Werner, Rohan Medhekar, Shuchita Kaila, Annelore Cortoos, Trevor Heritage
Health-Related Quality of Life in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Data From the PERSEUS Trial of Subcutaneous Daratumumab Combined With Bortezomib, Lenalidomide, and Dexamethasone
Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, Phoebe Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Christoph Driessen, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Yanfang Liu, Jianping Wang, Emilie M.J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Eva G. Katz, Katharine Gries, Jiaqi Song, Kai Fai Ho, Paula Rodríguez-Otero, Joan Bladé, Philippe Moreau
Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the MajesTEC-1 Trial
Jeffrey V. Matous, Niels W.C.J. van de Donk, Albert L. Oriol, Alfred L. Garfall, Paula Rodriguez-Otero, Thomas Chalopin, Laura Rosiñol Dachs, Katarina Uttervall, María-Victoria Mateos, Danielle Trancucci, Natalia A. Quijano Cardé, Caroline Hodin, Tara Stephenson, Athena Zuppa, Katherine Chastain, Lionel Karlin
Initiating First-Line Fixed Duration Ibrutinib and Venetoclax in Patients With Chronic Lymphocytic Leukemia Improves Overall Survival Outcomes to Rates Approximating an Age-Matched General European Population
Paolo Ghia, Loic Ysebaert, Ann Janssens, Mohamed Fouad, Claudio A. Schioppa, José-Ángel Hernández-Rivas, Alessandra Tedeschi
JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models
Lorena Fontan, Adam Zwolak, Irene Guimerans-Lorenzo, Mariette Bekkers, Nicholas Hein, Nele Vloemans, Emanuele Trella, Tina Smets, Ivo Cornelissen, Alemu Assefa, Bie Verbist, Ricardo Amorim, Pankaj Seth, Ranjeet Prasad Dash, Leopoldo Luistro, Bethany Mattson, Matthew A. Dragovich, Michael Hedvat, Gregory L. Moore, John R. Desjarlais, Olivia Kutlu, Joseph Erhardt, Ulrike Philippar
Less Frequent Teclistamab Dosing in Responders: Modeling and Simulation Data from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma
Yue Guo, Jin Niu, Natalia A. Quijano Cardé, Liviawati Wu, Xin Miao, Shalla Hanson, Yaming Su, Carlos Pérez Ruixo, Deeksha Vishwamitra, Katherine Chastain, Mahesh Samtani, Weirong Wang, Nahor Haddish-Berhane
Life Years Gained from the FDA Accelerated Approval Program in Hematology: A Portfolio Model
Bridget Doherty, Agnes Benedict, Silas Martin, Gabor Szabo, Kinga Marczell
Long-Term Benefits in Patient-Reported Outcomes and Time to Next Antimyeloma Therapy of Ciltacabtagene Autoleucel Versus Standard of Care for Patients With Lenalidomide-Refractory Multiple Myeloma: Results From the Phase 3 CARTITUDE-4 Clinical Trial
Noffar Bar, Roberto Mina, Anne K. Mylin, Hisayuki Yokoyama, Hila Magen, Winfried Alsdorf, Monique C. Minnema, Leyla O. Shune, Iris Isufi, Simon J. Harrison, Urvi A. Shah, André De Champlain, Katherine S. Gries, Diana Chen, Quanlin Li, Tzu-Min Yeh, Ana Slaughter, Carolina Lonardi, Nina Benachour, Arnab Ghosh, William Deraedt, Martin Vogel, Nikoletta Lendvai, Nitin Patel, Octavio Costa Filho, Erika Florendo, Lionel Karlin, Katja C. Weisel
Patient Characteristics, Treatment Patterns and Early Outcomes of Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Initiated on Talquetamab: An Electronic Medical Record and Chart Review Study
Cesar Rodriguez, Hsien-Yen Chang, Yi-Hsuan Liu, Jinghua He, Hoa H. Le, Jessica Maitland, Alvi A. Rahman, Anabelle Tardif-Samson, Bronwyn Moore, Marie-Hélène Lafeuille, Saurabh N. Patel, Xinke Zhang
Pharmacodynamic Profiles of Patients With Newly Diagnosed vs Relapsed/ Refractory Multiple Myeloma Who Received Teclistamab or Talquetamab Plus Daratumumab and Lenalidomide in the Phase 1b MajesTEC-2 and MonumenTAL-2 Studies
Diana Cortés-Selva, Brendan Paul Hodkinson, Ashwini Kumar, Sheri Skerget, Gary E. Mason, Elizabeth Shearin, Hein Ludlage, Bas D. Koster, Colleen Kane, Thomas Renaud, Tobias Kampfenkel, Christoph Heuck, Bhoomika Thakkar, Farheen Zishan, Emma Searle, Hang Quach, Gayathri Ravi, Cyrille Hulin, Wojciech Janowski, Jesus G. Berdeja, Sébastien Anguille, Jeffrey V. Matous, Cyrille Touzeau, Anne-Sophie Michallet, Ajay K. Nooka, Tara Cochrane, Anita D’Souza, Peter M. Voorhees, Karthik Ramasamy, Aurore Perrot, Andrew Spencer, Gurdeep Parmar, Deeksha Vishwamitra
Pharmacodynamic Signatures and Correlatives of Response in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
Deeksha Vishwamitra, Sheri Skerget, Diana Cortes-Selva, Kalpana Bakshi, Lien Vandenberk, Weili Sun, Jaszianne Tolbert, Colleen Kane, Hein Ludlage, Bas D. Koster, Julie S. Larsen, Tobias Kampfenkel, Ching Li, Farheen Zishan, Thomas Prior, Luciano J. Costa, Jesus G. Berdeja, Cyrille Touzeau, Aurore Perrot, Emma Searle, Jeffrey V. Matous, Ajai Chari, Donna Reece, Manisha Bhutani, Bhagirathbhai R. Dholaria, Anita D’Souza, Thomas G. Martin, John T. McKay, Alfred L. Garfall, Amrita Y. Krishnan, Niels W.C.J. van de Donk, Nizar J. Bahlis, Ricardo M. Attar
Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
Christian Recher, Jenny O’Nions, Ibrahim Aldoss, Ana Alfonso Piérola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Martin Curtis, Nikki Daskalakis, Matteo Giovanni Della Porta, Hartmut Döhner, Amber D’Souza, James P. Dugan, Jordi Esteve Reyner, Matthew Exum, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Min Chul Kwon, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Giovanni Martinelli, Daniel Morillo Giles, Joseph Murphy, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sravanti Rangaraju, Christoph Röllig, Olga Salamero, Madhu Sanga, Tim Sauer, Emma Searle, Natalia Tovar, Trevor Tucker, Nicolas Vallet, Lachlin Vaughan, Gala Vega, Paresh Vyas, Andrew Wei
Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
Marc S. Raab, Niels Weinhold, K. Martin Kortüm, Jan Krönke, Lilli Podola, Uta Bertsch, Jan H. Frenking, Julia Mersi, Stefanie Huhn, Michael Hundemer, Gunhild Mechtersheimer, Roland Fenk, Katja C. Weisel, Natalie Schub, Florian Bassermann, Monika Engelhardt, Raphael Teipel, Mathias Hänel, Hans Salwender, Bas D. Koster, Elena Ershova, Caline Sakabedoyan, Isobel Barrott, Agnes Balogh, Sanjay Vara, Tobias Kampfenkel, Hartmut Goldschmidt, Hermann Einsele, Leo Rasche
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone vs Lenalidomide Alone in Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation: Safety Run-in Results From the EMN30/MajesTEC-4 Trial
Elena Zamagni, Tobias Silzle, Ivan A. Špička, Sabrin Tahri, Sarah Lonergan, Inger S. Nijhof, Antonietta Pia Falcone, Evangelos Terpos, Jakub Radocha, Roberto Mina, Güldane Cengiz Seval, Meral Beksac, Cesar Rodriguez, Marcelo C. Pasquini, Michel Delforge, Vania Hungria, Donna Reece, Philippe Moreau, Yael C. Cohen, Kihyunk Kim, Dominik Dytfeld, Jiří A-Minařík, Irene Strassl, Jelena Bila, Martin Schreder, Janusz Krawczyk, Fredrik Schjesvold, Caroline Cicin-Sain, Christoph Driessen, Gordon Cook, Lugui Qiu, Gonzalo Martin Garate, Agoston Gyula Szabo, Roman Hájek, Marc S. Raab, Silvia Mangiacavalli, Hermann Einsele, Andrew Spencer, Mario Boccadoro, Helen Vasalou, Lixia Pei, Yingqi Shi, Maria Krevvata, Ryan Gruber, Caline Sakabedoyan, Margaret Cobb, Jagoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels W.C.J. van de Donk
Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies
Thomas G. Martin, María-Victoria Mateos, Niels W.C.J. van de Donk, Zhen Cai, Weijun Fu, Alfred L. Garfall, Shinsuke Iida, Yoshiaki Kuroda, Ting Niu, Ajay K. Nooka, Surbhi Sidana, Katherine Chastain, Margaret Doyle, Kazuko Nishikawa, Yang Song, Hiroshi Yamazaki, Jianmin Zhuo, Yan Zhu, Juan Du, Tadao Ishida
Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings
Aimaz Afrough, Adeel M. Khan, Eric Chinaeke, Nina Kim, Jinghua He, Elissa E. Min, Bingcao Wu, Dee Lin, Agne Paner-Straseviciute, Laura Hester, Jessica Fowler, Sian Walker, Christina Hearty, Larry D. Anderson, Jr.
Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) as Front-Line Treatment: Results From A Multicenter Chart Review Study
Carlyn Rose Tan, Lucio Gordan, Rachel Dileo, Prerna Mewawalla, Sarah M. Larson, Faith E. Davies, David Oveisi, Niodita Gupta-Werner, Rohan Medhekar, Annelore Cortoos, Marjohn Amoon, Alvi Rahman, Claire Vanden Eynde, Marie-Helene Lafeuille, John Reitan, Gary Milkovich, Joseph Bubalo, Adam Forman, Douglas Sborov, Shuchita Kaila, Saad Z. Usmani
Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab
Brittany Grossi, Nina Kim, Monal Kohli, Bingcao Wu, Emeka Umeh, Dee Lin, Gideon Aweh, Emily Achter, Laura Hester, Sian Walker, Christina Hearty, Peter M. Voorhees
Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs after the First Year of FDA Approval
Rahul Banerjee, Nina Kim, Monal Kohli, Emeka Umeh, Dee Lin, Gideon Aweh, Jessica Fowler, Emily Achter, Laura Hester, Sian Walker, Christina Hearty, Bingcao Wu
Real-World Evidence of First-Line Therapy in Transplant Eligible Multiple Myeloma Patients: Insights From the CIMMA Study
María-Victoria Mateos, Fernando Escalante, Natalia Marin Huarte, Angela García-Porrero, Miguel Jesús Villanueva Forero, Rafael Ríos Tamayo, Antonia Sampol Mayol, Eugenio Giménez, José-Ángel Hernández-Rivas, Savana Research Group, Joaquin Martinez-Lopez
Real World Evidence on Patient Reported Outcomes Among Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Regimens in Frontline (1L)
Smith Giri, Liton Francisco, Nicole Rafalko, Niodita Gupta-Werner, Joshua Richman, Smita Bhatia, Kelly Godby, Gayathri Ravi, Susan Bal, Marjohn Armoon, Rohan Medhekar, Luciano J. Costa
Real-World Step-Up Dosing Practice for Patients Who Initiated Talquetamab in US Hospitals: An Analysis of the All-Payer US Hospital Administrative Premier Healthcare Database
Rahul Banerjee, Hsien-Yen Chang, Yi-Hsuan Liu, Hoa H. Le, Helen Pai, Saurabh N. Patel, Xinke Zhang
Real-World Talquetamab Utilization Patterns and Dose Schedules in the United States: An Analysis Using Claims Data
Rahul Banerjee, Ruibin Wang, Yi-Hsuan Liu, Jinghua He, Hoa H. Le, Saurabh N. Patel, Xinke Zhang
Real-World Treatment Patterns and Clinical Outcomes Among Patients with Diffuse Large B-Cell Lymphoma in a US Healthcare Claims Database
Mazyar Shadman, Jennifer S. Harper, Alex Bokun, Gloria H.J. Graf, Xiaoxiao Lu
Satisfaction and Experiences With Talquetamab: Results From Qualitative Patient and Physician Research
Beth M. Faiman, Cesar Rodriguez, Smith Giri, Christine Brittle, Jay R. Hydren, Karla Mariana Castro Bórquez, Maria Gambill, Ana M. Sahagun Sanchez Aldana, Jennifer M. Ahlstrom, Hoa H. Le, Saurabh N. Patel, Kathleen S. Gray, Xinke Zhang, Rafael Fonseca
Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and del(17p)
Farrukh T. Awan, Ran Liu, Hsin-Hui Huang, Matthew Bye, Kwang Woo Ahn, Gabriel Krigsfeld, Anat Raz, Heather R. Wolfe, Mehdi Hamadani
Subcutaneous Daratumumab (Dara) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients With Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results From the Phase 3 Andromeda Study
Efstathios Kastritis, Giovanni O. Palladini, Monique C. Minnema, Ashutosh D. Wechalekar, Arnaud Jaccard, Hans C. Lee, Vaishali Sanchorawala, Peter Mollee, Jin Lu, Stefan Schoenland, Moshe E Gatt, Kenshi Suzuki, Kihyun Kim, M. Teresa Cibeira, Manisha Bhutani, Meral Beksac, Edward Libby, Jason Valent, Vania Hungria, Michael Rosenzweig, Naresh Bumma, Antoine Huart, NamPhuong Tran, Jianping Wang, Yuping Chen, Sandra Y. Vasey, Jordan M. Schecter, Jessica Vermeulen, Raymond L. Comenzo, Giampaolo Merlini
Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination With Daratumumab and Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results From the Phase 1b MonumenTAL-2 Study
Ajay K. Nooka, Tara Cochrane, Anita D'Souza, Jeffrey V. Matous, Peter M. Voorhees, Karthik Ramasamy, Aurore Perrot, Andrew Spencer, Cyrille Hulin, Hang Quach, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Gary E. Mason, Thomas Renaud, Gurdeep Parmar
Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the MajesTEC-2 Cohort A and TRIMM‑2 Studies
Anita D’Souza, Luciano J. Costa, Jesús San-Miguel, Jesús G. Berdeja, Daniel Morillo Giles, Cyrille Touzeau, John T. McKay, Bhagirathbhai Dholaria, Thomas G. Martin, Aurore Perrot, Albert Oriol, Anna Sureda Balari, Thomas Prior, Debopriya Ghosh, Lijuan Kang, Julie S. Larsen, Hein Ludlage, Lien Vandenberk, Lingling Chen, Bas D. Koster, Weili Sun, Rachel Kobos, Emma Searle, Jeffrey V. Matous, Ajai Chari, Tobias Kampfenkel
Treatment With First-Line Ibrutinib Improves Overall Survival in Patients With Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials With 10 Years Of Follow-Up
Jan A. Burger, Neil E. Kay, John N. Allan, Paul M. Barr, Jacqueline C. Barrientos, Carolyn Owen, Victoria Wang, Hsin-Hui Huang, Lynne Neumayr, Christopher Abbazio, Gabriel S. Krigsfeld, Sneh Mody, Paolo Ghia, Tait D. Shanafelt
Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2–4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
Nieves Lopez-Muñoz, Noffar Bar, Joris Diels, Suzy Van Sanden, João Mendes, Seina Lee, Teresa Hernando, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J. Harrison, Urvi A. Shah
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.